Laboratory for the Study of Anxiety Disorders, University of Texas at Austin
Austin, Texas, 78712, United States
NCT Number: NCT04663672
This study evaluates whether a scent applied during exposure therapy and during subsequent sleep will increase the durability of treatment effects for individuals with fear of spiders, contamination, and enclosed spaces.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Austin, Texas, 78712, United States
Newly acquired memories encoded during wakefulness are spontaneously re-activated during sleep, resulting in synaptic potentiation and strengthening of the re-activated traces. Targeted memory reactivation (TMR) typically involves a period of initial learning in the presence of an olfactory or auditory contextual cue, coupled with later presentation of the cue during sleep to ostensibly facilitate memory reactivation and consolidation. Numerous studies have found evidence of improved task performance subsequent to cue-induced neuronal replay, however application of TMR to treatment of naturally acquired, clinically significant fear has been limited.
The present study will will provide a rigorous test of TMR's efficacy as an augmentative strategy for exposure therapy. It is hypothesized that participants who sleep in the presence of the same odor that they are exposed to during exposure therapy will exhibit reduced fear at follow up, relative to participants who sleep in the presence of a different odor, or a non-odorous control.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will sleep in the presence of the exposure scent, delivered by an Airwick Essential Oils diffuser
Participants will sleep in the presence of a novel scent, delivered by an Airwick Essential Oils diffuser
Participants will sleep in the presence of an odorless control vehicle, delivered by an Airwick Essential Oils diffuser
Participants will receive 40 minutes of in-vivo exposure therapy to feared targets in the presence of a distinctive exposure scent.
Time frame: Baseline (Day 1); Post-treatment (Day 1; immediately after treatment); One Week Follow-Up (Day 8; one week after treatment); One Month Follow-Up (Day 31; one month after treatment)
Change in subjective units of distress (0 = no fear, to 100 = extreme fear) and skin conductance in response to approaching a feared stimulus, from baseline to one month follow-up
Time frame: Baseline (Day 1); One Week Follow-Up (Day 8; one week after treatment); One Month Follow-Up (Day 31; one month after treatment)
Change in total score on the Fear of Spiders Questionnaire from baseline to one month follow-up
Time frame: Baseline (Day 1); One Week Follow-Up (Day 8; one week after treatment); One Month Follow-Up (Day 31; one month after treatment)
Change in total score on the Claustrophobia Questionnaire from baseline to one month follow-up
Time frame: Baseline (Day 1); One Week Follow-Up (Day 8; one week after treatment); One Month Follow-Up (Day 31; one month after treatment)
Change in total score on the contamination subscale of the Padua Inventory- Washington State University Revision from baseline to one month follow-up
University of Texas at Austin
Other
Placebo-Controlled, Randomized, Double-Blind Study of the Efficacy of Targeted Memory Reactivation for Enhancing Exposure Therapy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03384849
Anxiety, Anxiety Disorders
Warsaw, Poland
View Trial DetailsNCT04536116
Anxiety Disorders, Claustrophobia
Vandœuvre-lès-Nancy, France
View Trial DetailsNCT04754958
Anxiety Disorders, Claustrophobia
Geneva, Switzerland
View Trial DetailsNCT02926352
Anxiety Disorders, Claustrophobia
Austin, Texas, United States
View Trial Details